Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells

被引:938
作者
Lund, J
Sato, A
Akira, S
Medzhitov, R
Iwasaki, A
机构
[1] Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA
[3] Osaka Univ, SORST, Japan Sci & Technol Corp, Microbial Dis Res Inst,Dept Host Def, Suita, Osaka 5650871, Japan
关键词
type I interferons; CpG motif; innate immunity; virus infection; DNA virus;
D O I
10.1084/jem.20030162
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Plasmacytoid dendritic cells (pDCs) have been identified as a potent secretor of the type I interferons (IFNs) in response to CpG as well as several viruses. In this study, we examined the molecular mechanism of virus recognition by pDCs. First, we demonstrated that the CD11c(+)Gr-1(int)B220(+) pDCs from mouse bone marrow secreted high levels of IFN-alpha in response to either live or UV-inactivated Herpes simplex virus-2 (HSV-2). Next, we identified that IFN-alpha secretion by pDCs required the expression of the adaptor molecule MyD88, suggesting the involvement of a Toll-like receptor (TLR) in HSV-2 recognition. To test whether a TLR, mediates HSV-2-induced IFN-alpha. secretion from pDCs, various knockout mice were examined. These experiments revealed a clear requirement for TLR9 in this process. Further, we demonstrated that purified HSV-2 DNA can trigger IFN-alpha secretion from pDCs and that inhibitory CpG oligonucleotide treatment diminished HSV-induced IFN-alpha secretion by pDCs in a dose-dependent manner. The recognition of HSV-2 by TLR9 was mediated through an endocytic pathway that was inhibited by chloroquine or bafilomycin A1. The strict requirement for TLR9 in IFN-alpha secretion was further confirmed by the inoculation of HSV-2 in vivo. Therefore, these results demonstrate a novel mechanism whereby the genomic DNA of a virus can engage TLR9 and result in the secretion of IFN-alpha by pDCs.
引用
收藏
页码:513 / 520
页数:8
相关论文
共 34 条
[1]   Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function [J].
Adachi, O ;
Kawai, T ;
Takeda, K ;
Matsumoto, M ;
Tsutsui, H ;
Sakagami, M ;
Nakanishi, K ;
Akira, S .
IMMUNITY, 1998, 9 (01) :143-150
[2]  
Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO
[3]  
2-U
[4]   Mouse type IIFN-producing cells are immature APCs with plasmacytoid morphology [J].
Asselin-Paturel, C ;
Boonstra, A ;
Dalod, M ;
Durand, I ;
Yessaad, N ;
Dezutter-Dambuyant, C ;
Vicari, A ;
O'Garra, A ;
Biron, C ;
Brière, F ;
Trinchieri, G .
NATURE IMMUNOLOGY, 2001, 2 (12) :1144-1150
[5]   Virus-induced interferon α production by a dendritic cell subset in the absence of feedback signaling in vivo [J].
Barchet, W ;
Cella, M ;
Odermatt, B ;
Asselin-Paturel, C ;
Colonna, M ;
Kalinke, U .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (04) :507-516
[6]   Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: Dependency on antigen dose and differential toll-like receptor ligation [J].
Boonstra, A ;
Asselin-Paturel, C ;
Gilliet, M ;
Crain, C ;
Trinchieri, G ;
Liu, YJ ;
O'Garra, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (01) :101-109
[7]   Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs [J].
Brawand, P ;
Fitzpatrick, DR ;
Greenfield, BW ;
Brasel, K ;
Maliszewski, CR ;
De Smedt, T .
JOURNAL OF IMMUNOLOGY, 2002, 169 (12) :6711-6719
[8]   Estimates of the incidence and prevalence of sexually transmitted diseases in the United States [J].
Cates, W .
SEXUALLY TRANSMITTED DISEASES, 1999, 26 (04) :S2-S7
[9]   Interferon α/β and interleukin 12 responses to viral infections:: Pathways regulating dendritic cell cytokine expression in vivo [J].
Dalod, M ;
Salazar-Mather, TP ;
Malmgaard, L ;
Lewis, C ;
Asselin-Paturel, C ;
Brière, F ;
Trinchieri, G ;
Biron, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (04) :517-528
[10]  
Eloranta ML, 1999, SCAND J IMMUNOL, V49, P391